LONDON, Aug. 20, 2014 /PRNewswire/ -- GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta ® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS ...
The US Food and Drug Administration (FDA) has approved fluticasone furoate inhalation powder (Arnuity Ellipta, GlaxoSmithKline) as maintenance treatment for asthma in patients aged 12 years and older, ...
The FDA has approved fluticasone furoate inhalation powder as a once-daily corticosteroid for maintenance treatment of asthma in patients aged 12 and older, according to a press release. Fluticasone ...
Arnuity™ Ellipta® now available in the US for once-daily treatment of asthma. Incruse® Ellipta® now available in the US for once-daily treatment for COPD. GlaxoSmithKline plc (LSE/NYSE: GSK) today ...
GlaxoSmithKline announced that the Food and Drug Administration (FDA) has approved Arnuity Ellipta (fluticasone furoate inhalation powder) for the maintenance treatment of asthma as prophylactic ...
Please provide your email address to receive an email when new articles are posted on . GlaxoSmithKline announced that the FDA has approved Arnuity Ellipta, a once-daily inhaled corticosteroid, for ...
New Inhalers for Asthma, COPD Launched by GSK GlaxoSmithKline announced the launch of Arnuity Ellipta (fluticasone furoate inhalation powder) and Incruse Ellipta (umeclidinium bromide inhalation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback